Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial

AIM: The sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved clinical outcomes in patients hospitalized for acute heart failure. In patients with chronic heart failure, SGLT2 inhibitors cause an early decline in estimated glomerular filtration rate (eGFR) followed by a slower eGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Voors, Adriaan A., Damman, Kevin, Teerlink, John R., Angermann, Christiane E., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, Ponikowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Focused Issue on Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828037/
https://www.ncbi.nlm.nih.gov/pubmed/36066557
http://dx.doi.org/10.1002/ejhf.2681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828037/
https://www.ncbi.nlm.nih.gov/pubmed/36066557
http://dx.doi.org/10.1002/ejhf.2681

Ejemplares similares